Cradle Bio vs Umoja Biopharma

Side-by-side comparison of AI visibility scores, market position, and capabilities

Umoja Biopharma leads in AI visibility (41 vs 20)
Cradle Bio logo

Cradle Bio

EmergingLife Sciences & BioTech

AI Protein Engineering

Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial and therapeutic use.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
24
Perplexity
17
Gemini
15

About

Cradle Bio is an AI protein engineering company founded in 2021 in Amsterdam, having raised $73M to build an AI-powered protein design platform. The platform combines generative AI with wet-lab experimentation to accelerate the iterative process of engineering proteins with improved stability, activity, and manufacturability. Cradle's technology enables researchers to design thousands of protein variants computationally and prioritize those most likely to succeed in laboratory validation, compressing protein engineering timelines from years to months. The company serves both industrial biotechnology customers engineering enzymes for biomanufacturing and pharmaceutical companies developing next-generation antibody therapeutics. Cradle partners with contract research organizations and biopharmaceutical companies to integrate AI-assisted protein design into existing discovery workflows. The company has been recognized as a leader in the European deep tech ecosystem and positions protein engineering AI as enabling a new era of designed biologics for medicine and sustainable manufacturing.

Full profile
Umoja Biopharma logo

Umoja Biopharma

EmergingBioTech

Cell Therapy

Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the need for cell extraction and manufacturing.

AI VisibilityBeta
Overall Score
C41
Category Rank
#2 of 2
AI Consensus
58%
Trend
up
Per Platform
ChatGPT
34
Perplexity
38
Gemini
40

About

Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price.

Full profile

AI Visibility Head-to-Head

20
Overall Score
41
#1
Category Rank
#2
64
AI Consensus
58
up
Trend
up
24
ChatGPT
34
17
Perplexity
38
15
Gemini
40
30
Claude
50
21
Grok
32

Key Details

Category
AI Protein Engineering
Cell Therapy
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Cradle Bio
AI Protein Engineering
Only Umoja Biopharma
Cell Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.